The safety and interpretability of skin tests with omalizumab.
Phillip
P
Lieberman
Abdelkader
A
Rahmaoui
Dennis A
DA
Wong
D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D015331:Cohort Studies; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology*; D005079:Excipients / Q000009:adverse effects*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab; D012882:Skin Tests / Q000009:adverse effects*
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005079:Excipients; D000069444:Omalizumab; D007073:Immunoglobulin E